{"title": "Julius Chapiro", "author": "Julius Chapiro", "url": "https://www.yalemedicine.org/specialists/julius-chapiro", "hostname": "yalemedicine.org", "description": "Julius Chapiro, MD, is an interventional radiologist who specializes in treating patients with liver cancer. As a physician-scientist, his research focuses on developing new imaging biomarkers to diagnose, characterize, and treat liver cancer. Dr. Chapiro's works includes creating advanced molecular imaging methods and incorporating machine-learning approaches. In addition to his clinical work and research, Dr. Chapiro is an associate editor for the Journal of Hepatology and a member of the American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) Steering Committee. He is also the co-initiator of the Rising Star Student Exchange Program in collaboration with the Charit\u00e9 University Hospital in Berlin and co-directs the Yale Interventional Oncology Research Laboratory. Dr. Chapiro is an assistant professor at Yale School of Medicine in Radiology, Digestive Diseases, and Biomedical Engineering. He is the associate director of the Clinical Core of the Yale Liver Center.", "sitename": "Yale Medicine", "date": "2023-01-01", "cleaned_text": "Julius Chapiro, MD/PhD Biography Julius Chapiro, MD, is an interventional radiologist who specializes in treating patients with liver cancer. As a physician-scientist, his research focuses on developing new imaging biomarkers to diagnose, characterize, and treat liver cancer. Dr. Chapiro's works includes creating advanced molecular imaging methods and incorporating machine-learning approaches. In addition to his clinical work and research, Dr. Chapiro is an associate editor for the Journal of Hepatology and a member of the American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) Steering Committee. He is also the co-initiator of the Rising Star Student Exchange Program in collaboration with the Charit\u00e9 University Hospital in Berlin and co-directs the Yale Interventional Oncology Research Laboratory. Dr. Chapiro is an assistant professor at Yale School of Medicine in Radiology, Digestive Diseases, and Biomedical Engineering. He is the associate director of the Clinical Core of the Yale Liver Center. Titles - Associate Professor of Radiology and Biomedical Imaging - Associate Professor , Digestive Diseases - Associate Professor , Biomedical Engineering - Principal Investigator, Yale Interventional Oncology Laboratory , Radiology & Biomedical Imaging - Director, Center for Minimally Invasive Therapies, Radiology & Biomedical Imaging - Associate Director, Clinical and Translational Core, Liver Center Education & Training - MD/PhDUniversity of Leipzig - Interventional Radiology ResidentYale New Haven Hospital - Diagnostic Radiology ResidentCharit\u00e9 Universit\u00e4tsmedizin Berlin - Research Fellow in Interventional OncologyThe Johns Hopkins Hospital Languages Spoken - English - Fran\u00e7ais (French) - Deutsch (German) - (Russian) Additional Information [Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion](http://www.ncbi.nlm.nih.gov/pubmed/37439935)Taouli B, Ba-Ssalamah A, Chapiro J, Chhatwal Fowler K, Kang T, Knobloch G, Koh D, Kudo M, Lee J, Murakami T, Pinato D, Ringe K, Song B, Tabrizian P, Wang J, Yoon J, Zeng M, Zhou J, Vilgrain V. Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team 10.1007/s00330-023-09919-z](https://doi.org/10.1007/s00330-023-09919-z). [Predicting tumor baseline MR imaging in patients with early-stage hepatocellular carcinoma using deep machine learning](http://www.ncbi.nlm.nih.gov/pubmed/37165035)Kucukkaya A, Zeevi T, Chai N, Raju R, Haider S, Elbanan M, Petukhova-Greenstein A, Lin M, Onofrey J, Nowak M, Cooper K, Thomas E, Santana J, Gebauer B, Mulligan D, Staib L, Batra R, Chapiro J. Predicting tumor recurrence on baseline MR imaging in patients with early-stage hepatocellular carcinoma using deep machine learning V, Madoff D, Zhang X, Chapiro J. Experimental VX2 Rabbit Liver Tumor Model in Carbon Tetrachloride-Induced Cirrhosis of the Liver Journal Score Comparison of Efficacy and Safety](https://doi.org/10.3390/cancers14235847)Savic L, Chen E, Nezami N, Murali N, Hamm C, Wang C, Lin M, Schlachter T, Hong K, Georgiades C, Chapiro Hepatocellular Carcinoma\u2014A Propensity Score Comparison of Efficacy and Safety](http://www.ncbi.nlm.nih.gov/pubmed/36497329)Savic L, Chen E, Nezami N, Murali N, Hamm C, Wang C, Lin M, Schlachter T, Hong K, Georgiades C, Chapiro J, Unresectable Hepatocellular Carcinoma\u2014A Propensity after Radiofrequency Ablation of the Liver](http://www.ncbi.nlm.nih.gov/pubmed/36423815)Santana J, Petukhova-Greenstein A, Gross M, Hyder F, Pekurovsky V, Gottwald L, Boustani A, Walsh J, Kucukkaya A, Malpani R, Madoff D, Goldberg S, Ahmed M, Joshi N, Coman D, Chapiro J. MR Imaging-Based In Vivo Macrophage Imaging to Monitor Immune Response after Radiofrequency Ablation of the Liver Journal radiation therapy of hepatocellular carcinoma: an international expert study](http://www.ncbi.nlm.nih.gov/pubmed/36282299)Gregory J, Tselikas L, Allimant C, de Baere T, Bargellini I, Bell J, Bilbao JI, Bouvier A, Chapiro J, Chiesa C, Decaens J, Helmberger T, Irani F, Lam M, Lewandowski R, Liu D, Loffroy R, Madoff DC, Mastier C, Salem R, Sangro B, Sze D, Vilgrain V, Vouche M, Guiu B, Ronot M. Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study European Journal Of Nuclear Medicine And Molecular Imaging 2022, 50: 921-928. [PMID: Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical Study.](http://www.ncbi.nlm.nih.gov/pubmed/35975886)Iseke S, Zeevi Kucukkaya Haider SP, Petukhova-Greenstein A, Kuhn TN, Lin M, Nowak M, Cooper K, Thomas E, Weber MA, Madoff DC, Staib L, Batra R, Chapiro J. Machine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective van Breugel JMM, S, Rexha I, Tegel LJ, Hong K, Georgiades C, Nezami N. Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A of Interventional Radiology Foundation Research Consensus Panel on Artificial Intelligence in Interventional Radiology: From Code to Bedside](http://www.ncbi.nlm.nih.gov/pubmed/35871021)Chapiro J, Allen B, Abajian A, Wood B, Kothary N, Daye D, Bai H, Sedrakyan A, Diamond M, Simonyan V, McLennan G, Abi-Jaoudeh N, Pua B. Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel on Artificial Intelligence in Interventional Radiology: From Code to Bedside Journal Of P, Camacho JC, Nezami N. Intraarterial Therapies Chapiro Georgiades C, Hong KK, Nezami N. Response assessment methods for patients with hepatic metastasis from rare tumor primaries after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features](http://www.ncbi.nlm.nih.gov/pubmed/35460887)Petukhova-Greenstein A, Zeevi T, Yang J, Chai N, DiDomenico P, Deng Y, Ciarleglio M, Haider SP, Onyiuke I, Malpani R, Lin G, Taddei T, Chapiro J. MR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features Journal Of for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at T, Nezami N, Strazzabosco Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden towards AI-driven predictive biomarkers for immunotherapy of hepatocellular carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/35417743)Chapiro J. Translating artificial intelligence from code to bedside: The road towards AI-driven predictive biomarkers for on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model](http://www.ncbi.nlm.nih.gov/pubmed/35346859)Berz JG, Iseke M, Zhang X, Schlachter T, Madoff DC, Chapiro J. Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor intelligence liver improving Imaging Acquired during Transarterial Chemoembolization for Liver Tumors: A Deep Learning Approach](http://www.ncbi.nlm.nih.gov/pubmed/34923098)Malpani R, Petty CW, Yang J, Bhatt N, Zeevi T, Chockalingam V, Raju JG, Schlachter TR, Madoff DC, Chapiro J, Duncan J, Lin M. Quantitative Automated Segmentation of Lipiodol Deposits on Cone-Beam CT Imaging Acquired during Transarterial Chemoembolization for Liver Tumors: A Deep Learning Approach Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative.](http://www.ncbi.nlm.nih.gov/pubmed/34581627)Puijk RS, Ahmed M, Adam A, Arai Y, Arellano R, de Ba\u00e8re T, Bale R, Bellera Binkert Brace DJ, E, Gangi A, Gervais DA, Gillams AR, Greene T, Guiu B, Helmberger T, Iezzi R, Kang TW, Kelekis A, Kim HS, Kr\u00f6ncke T, Kwan S, Lee MW, Lee FT, Lee EW, Liang P, Lissenberg-Witte BI, Lu DS, Madoff DC, Mauri G, Meloni MF, Morgan R, Nadolski G, Narayanan G, Newton I, Nikolic B, Orsi F, Pereira PL, Pua U, Rhim H, W, TJ, Wang DS, Wood BJ, Goldberg SN, Meijerink MR. Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging](http://www.ncbi.nlm.nih.gov/pubmed/34852007)Gross M, Spektor M, Jaffe A, Kucukkaya AS, Iseke S, Haider SP, Strazzabosco M, Chapiro J, Onofrey JA. Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure](http://www.ncbi.nlm.nih.gov/pubmed/34804911)Frangakis C, Sohn JH, Bas A, Chapiro J, Schernthaner RE, Lin M, Hamilton JP, Pawlik TM, Hong K, Duran R. Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Recurrent Hepatocellular Carcinoma: Worth the Risk?](http://www.ncbi.nlm.nih.gov/pubmed/34717834)Nam D, Chapiro J. Machine Learning-Based Surveillance Strategy after Complete Ablation of Initially Recurrent Hepatocellular Carcinoma: Worth the chemoembolic in CA, Gebauer B, Walsh JJ, Rexha I, Hyder F, Lin M, Madoff DC, Schlachter T, Chapiro J, Coman D. Comparison of responses to transarterial chemoembolization with different chemoembolic regimens in M, Hong K, Georgiades C. Lipiodol Deposition and Washout in Primary and Interventional Radiology: Current State and Future Directions](http://www.ncbi.nlm.nih.gov/pubmed/35005333)Malpani R, Petty C, Bhatt N, Staib L, Chapiro J. Use of Artificial Intelligence in Nononcologic Interventional Radiology: Current State and Future in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy](http://www.ncbi.nlm.nih.gov/pubmed/34061209)Ghani MA, Fereydooni A, Chen E, Letzen B, Laage-Gaupp F, Nezami N, Deng Y, Gan G, Thakur V, Lin M, Papademetris X, Schernthaner RE, Huber S, Chapiro J, Hong K, Georgiades C. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial](http://www.ncbi.nlm.nih.gov/pubmed/34022765)Letzen BS, R, Miszczuk M, de Ruiter QMB, Petty Rexha Nezami Laage-Gaupp F, M, Schlachter TR, Chapiro J. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma](http://www.ncbi.nlm.nih.gov/pubmed/33927226)Rexha I, Laage-Gaupp F, Konstantinidis Duran R, Gebauer B, Georgiades C, Hong K, Nezami N. Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of SPION-Enhanced J, Savic Hepatic Radiofrequency Ablation: Monitoring the DC, Robinson SP, Karst U, Buchholz R, Keller S, Hamm B, Goldberg SN, MR. Elastin-specific MRI of extracellular matrix-remodelling following hepatic truth: Application to intraprocedural CBCT/MR liver segmentation and registration](http://www.ncbi.nlm.nih.gov/pubmed/33823397)Zhou B, Augenfeld Z, Chapiro J, Zhou SK, Liu C, Duncan JS. Anatomy-guided multimodal registration by learning segmentation without ground truth: Application to intraprocedural CBCT/MR liver segmentation and patients with small (<3 cm) hepatocellular carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/33592550)Chai Chapiro J, Petukhova Zeevi T, Elbanan M, M, JS, Madoff vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 After Transarterial Chemoembolization](http://www.ncbi.nlm.nih.gov/pubmed/33484726)Wu X, Chapiro J, Malhotra A. Cost-Effectiveness of Imaging Tumor Response Criteria in Hepatocellular Cancer After Transarterial Chemoembolization Journal Of hepatocellular carcinoma (HCC) versus non-HCC on of the liver](http://www.ncbi.nlm.nih.gov/pubmed/33409782)Oestmann PM, Wang CJ, Savic LJ, Hamm CA, Stark S, Schobert I, Gebauer Schlachter T, Lin M, Weinreb JC, Batra R, Mulligan D, Zhang X, Duncan JS, Chapiro J. Deep learning-assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on Trilla A, M\u00e4hringer-Kunz A, Hahn F, D\u00fcber C, Becker B, Dos Santos DP, Kloeckner R. How COVID-19 kick-started online learning of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice Cost-Effectiveness Analysis](http://www.ncbi.nlm.nih.gov/pubmed/33160827)Wu Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on LA, J, T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on Improved Probability Calibration and Classification](http://www.ncbi.nlm.nih.gov/pubmed/32356739)Zhang F, Dvornek N, Yang J, Chapiro J, Duncan J. Layer Embedding Analysis in Convolutional Neural Networks for Improved Probability Calibration and Classification IEEE biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer](http://www.ncbi.nlm.nih.gov/pubmed/33093524)Stark S, Wang M, Murali Gebauer B, Lin M, Duncan J, Schlachter T, Chapiro J. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer marker for doxorubicin pharmacokinetics during transarterial JH, S, P, MA, Perez Lozada JC, Ayyagari R, Pollak J, Schlachter T. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma](http://www.ncbi.nlm.nih.gov/pubmed/32938221)Auer TA, Della Seta M, Collettini F, Chapiro J, Zschaeck Ghadjar P, Badakhshi H, Florange J, Hamm B, Budach V, Kaul D. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients Field Correction Effect on 3D-quantitative Image Analysis](http://www.ncbi.nlm.nih.gov/pubmed/33083252)Liu C, Smolka S, Papademetris X, Do Minh D, Gan G, Deng Y, Lin M, Chapiro J, Wang X, Georgiades C, Hong K. Predicting Infiltrative Hepatocellular Carcinoma Patient Outcome Post-TACE: MR Bias Field Correction Effect on 3D-quantitative Image Analysis Journal Of Clinical Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment](http://www.ncbi.nlm.nih.gov/pubmed/32684417)Borde Gaupp F, Geschwind JF, Savic LJ, Miszczuk M, I, Adam L, Walsh JJ, Huber S, Duncan JS, Peters DC, Sinusas A, Schlachter T, Chemoembolization in a Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment Journal Of Vascular a Rabbit Liver Tumor Model: A Biomarker Resistance Mechanisms in Tumor-targeted Therapy?](http://www.ncbi.nlm.nih.gov/pubmed/32633675)Savic LJ, Doemel LA, Schobert IT, Montgomery RR, Joshi N, Walsh JJ, Santana J, Pekurovsky V, Zhang X, Lin M, Adam L, Boustani A, Duncan J, Leng L, Bucala RJ, Goldberg SN, Hyder F, Coman D, Chapiro J. Molecular MRI of the Immuno-Metabolic Interplay in a Rabbit Liver Tumor Model: A Biomarker using LH, M, J, Lin M. detection and delineation of hepatocellular carcinoma on multiphasic contrast-enhanced MRI correlation](http://www.ncbi.nlm.nih.gov/pubmed/32430483)Tefera J, Revzin Mulligan D, X. hepatocellular carcinoma\u2014a new variant of liver cancer: clinical, pathological and radiological correlation Journal Of carcinoma after DEB-TACE](http://www.ncbi.nlm.nih.gov/pubmed/32424595)Schobert IT, Savic LJ, Chapiro Chen Nezami N, Lin M, Pollak J, Schlachter T. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in biomarker for disease progression of renal cell carcinoma after tumor ablation](http://www.ncbi.nlm.nih.gov/pubmed/32216452)Tegel BR, Huber S, Savic LJ, Lin M, Gebauer B, Pollak J, Chapiro J. Quantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after Chapiro J. Supervised Machine Learning in Oncology: A Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32092672)Miszczuk MA, Chapiro J, Geschwind JH, E, Schlachter T. Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment](http://www.ncbi.nlm.nih.gov/pubmed/31582517)Savic LJ, Schobert I, Peters D, Walsh JJ, Laage-Gaupp F, Hamm CA, Tritz N, Doemel LA, Lin M, Sinusas A, Schlachter T, Duncan JS, Hyder F, Coman D, Chapiro J. Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment Clinical cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT?](http://www.ncbi.nlm.nih.gov/pubmed/31811428)Luedemann WM, Geisel Gebauer B, Schnapauff D, Chapiro J. Comparing HCC tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ Pua U. Interventional oncology: aiming globally to be the 4 th pillar of cancer care Chinese Clinical Oncology 2019, 8: Lower Urinary Tract Symptoms Attributable to Benign Prostatic Hyperplasia: A Single-Center Outcomes Analysis with Medium-Term Follow-up](http://www.ncbi.nlm.nih.gov/pubmed/31771896)Ayyagari R, Powell T, Staib L, Chapiro J, Raja A, Bhatia S, Chai T, S, R. Prostatic Artery Embolization Using 100-300-m Trisacryl Gelatin Microspheres to Treat Lower Urinary Tract Symptoms Attributable to Benign Prostatic Hyperplasia: A Single-Center Outcomes Analysis with Medium-Term R, Powell T, Staib L, Chapiro J, Perez-Lozada JC, Bhatia S, Chai T, Schoenberger S, C, Collettini F, Sack I, Savic LJ, Hamm B, Goldberg SN, Makowski M. Quantitative MRI for Assessment of Treatment Outcomes in a Rabbit VX2 Hepatic Tumor Model Journal Of Magnetic Resonance 668-685. [PMID: 31713973](https://pubmed.ncbi.nlm.nih.gov/31713973), [DOI: Savic LJ, Huber S, Sinusas AJ, Lin M, Chapiro J, Constable RT, Rothman DL, Duncan JS, Hyder F. Extracellular pH mapping of liver cancer on a clinical 3T MRI scanner Magnetic Resonance In Liver Segmentation](http://www.ncbi.nlm.nih.gov/pubmed/32377643)Yang J, Dvornek NC, Zhang F, Chapiro J, Lin M, Duncan JS. Unsupervised Domain Adaptation via Disentangled Representations: NC, Zhang F, Zhuang J, Chapiro J, Lin M, Duncan JS. Domain-Agnostic Learning with Anatomy-Consistent Embedding for to Bedside: Introducing Predictive Intelligence to Interventional Oncology Radiology Primary and Metastatic D, Saperstein to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Embolization for Treatment of Benign Hyperplasia](http://www.ncbi.nlm.nih.gov/pubmed/31375451)Ayyagari R, Powell T, Staib L, Chapiro J, Schoenberger Devito R, versus Balloon-Occlusion Microcatheter Artery Embolization for Treatment of Benign M, Chapiro J. application of lipiodol for transarterial chemoembolization in neural network interpretation JC, Duncan JS, Chapiro J, Letzen B. Deep learning for liver tumor diagnosis part II: convolutional neural network interpretation using of a convolutional neural JS, Weinreb JC, Chapiro J, Letzen B. Deep learning for liver tumor diagnosis part I: development of a convolutional neural network Interventional Oncology White Paper](http://www.ncbi.nlm.nih.gov/pubmed/31012818)Erinjeri JP, Fine GC, GJ, Ahmed J, Brok M, Duran R, Hunt SJ, Johnson DT, Ricke J, Sze DY, Toskich BB, Wood BJ, Woodrum D, Goldberg SN. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities\u2014A Society pre-treatment MRI predicts overall survival after stereotactic radiation therapy of patients with a singular brain metastasis](http://www.ncbi.nlm.nih.gov/pubmed/30841703)Della Seta M, Collettini F, Chapiro J, Angelidis A, Engeling F, Hamm B, Kaul D. A 3D quantitative imaging biomarker in pre-treatment MRI predicts overall survival after stereotactic radiation therapy of patients with a singular Chapiro Nezami Gebauer M, Pollak J, Saperstein L, Schlachter T, Bremsstrahlung J. The Role of Artificial Intelligence in Interventional Oncology: A Primer Journal Of Vascular Prospective Single-Center Phase I Study](http://www.ncbi.nlm.nih.gov/pubmed/30337148)Fereydooni A, Letzen B, Ghani MA, Cancer Liver Metastases: A Prospective Single-Center Phase I Study Journal Of Learning: An Example for Trans-Arterial Geschwind JF, Chapiro J. Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma. Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma](https://doi.org/10.3791/58382-v)Abajian A, Murali N, Savic L, Laage-Gaupp F, Nezami Duncan J, Schlachter T, Lin M, Geschwind J, Chapiro J. Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma Journal Of Visualized Experiments 2018 [DOI: 10.3791/58382-v](https://doi.org/10.3791/58382-v). [Liver Tissue Classification Using an Auto-context-based Deep Neural Network with a Multi-phase Training Framework](http://www.ncbi.nlm.nih.gov/pubmed/32432233)Zhang F, Yang J, Nezami N, Laage-gaupp F, Chapiro J, De Lin M, Duncan J. Liver Tissue Classification Using an Auto-context-based Deep Neural Network with a Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning\u2014An Artificial Intelligence Concept](http://www.ncbi.nlm.nih.gov/pubmed/29548875)Abajian A, Murali Geschwind JF, Chapiro J. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning\u2014An Artificial Intelligence Concept Journal Of Vascular Streitparth F. Off-Target Effects-Is Network Pathway Analysis the Final Piece of the Puzzle?](http://www.ncbi.nlm.nih.gov/pubmed/29356646)Murali N, Laage-Gaupp FM, Chapiro J, Geschwind Enigma of Ablation-induced Off-Target Effects-Is Network Pathway Analysis the Final Delivery in Combination X-Ray Imaging System for Interventional Procedures: Improved Image Quality and Reduced Radiation Dose](http://www.ncbi.nlm.nih.gov/pubmed/29090348)Schernthaner RE, Haroun RR, Nguyen S, Duran R, Sohn JH, Sahu S, Chapiro J, Zhao Y, Radaelli A, van der Bom IM, Mauti M, Hong K, Geschwind JH, Lin M. Characteristics of a New X-Ray Imaging System for Interventional Procedures: Improved Image Quality and Reduced Radiation Dose CardioVascular 3D Guidance in Portal Vein Embolization (PVE)](http://www.ncbi.nlm.nih.gov/pubmed/28875339)L\u00fcdemann WM, B\u00f6ning G, Chapiro Cone Beam CT for Intraprocedural Image Fusion and 3D Guidance in Portal Vein Embolization Carcinoma by Fusing Structured and Rotationally Invariant Context Representation](http://www.ncbi.nlm.nih.gov/pubmed/29900427)Treilhard J, Smolka S, Staib L, Chapiro J, Lin M, Shakirin G, Duncan J. Liver Tissue Classification in Patients with Hepatocellular Carcinoma by Fusing Structured and before Transarterial Chemoembolization](http://www.ncbi.nlm.nih.gov/pubmed/28747271)Jonczyk M, Chapiro J, Collettini F, Geisel D, Schnapauff D, Streitparth F, Schmidt T, Hamm B, Gebauer B, G. Diagnostic Accuracy of Split-Bolus Single-Phase Contrast-Enhanced Cone-Beam CT for the Detection of Liver yttrium-90 radioembolisation as treatment options using a propensity score analysis model](http://www.ncbi.nlm.nih.gov/pubmed/28677067)Do Minh D, Chapiro J, Gorodetski B, Huang Q, Liu C, Smolka S, Savic LJ, yttrium-90 radioembolisation as treatment options with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/28668723)Smolka S, Chapiro J, Manzano W, Treilhard J, Reiner E, Deng Y, Zhao Y, Hamm B, Duncan JS, Gebauer B, Lin M, Geschwind JF. The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma to Complete Response in Chemoembolization?](http://www.ncbi.nlm.nih.gov/pubmed/28514219)Savic LJ, Chapiro J, Dormant Cells\u2014Is Targeting Autophagy the Key to J, J, M, CP, JF. Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with therapies for liver cancer: assessing tumor response Expert Review 119-127. [PMID: 27983883](https://pubmed.ncbi.nlm.nih.gov/27983883), [DOI: 10.1080/14737140.2017.1273775](https://doi.org/10.1080/14737140.2017.1273775). [Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy](http://www.ncbi.nlm.nih.gov/pubmed/27847278)Sohn JH, Duran R, Zhao Y, Fleckenstein F, Chapiro J, Sahu S, Schernthaner RE, Qian T, Lee H, Zhao L, Hamilton J, Frangakis C, Lin M, Salem R, Geschwind JF. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy Clinical Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?](http://www.ncbi.nlm.nih.gov/pubmed/27831830)Sahu S, Schernthaner R, Ardon R, Chapiro J, Zhao JH, F, Lin M, Geschwind JF, Duran R. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Geschwind JH. From the Guest Editor JF. Interventional Oncology S, Fleckenstein F, Smolka S, Pawlik TM, Schernthaner R, Zhao L, Lee H, He S, Lin M, Geschwind JF. Transarterial Chemoembolization for the Treatment of Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis](http://www.ncbi.nlm.nih.gov/pubmed/27641641)Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Marshall K, Lin M, Gebauer B, Chapiro J, Salem R, Geschwind JF. Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement and Myths Exposed?](http://www.ncbi.nlm.nih.gov/pubmed/27429140)Chapiro J, Geschwind JF. Science to Practice: Systemic Implications of Sorafenib in Combination Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma. Clinical And [PMID: 27487101](https://pubmed.ncbi.nlm.nih.gov/27487101). Metastatic in During Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam CT](http://www.ncbi.nlm.nih.gov/pubmed/27380872)Schernthaner RE, Haroun Duran R, Lee Sahu Sohn JH, Chapiro J, Zhao Y, Gorodetski B, Fleckenstein F, Smolka S, Radaelli A, van der Bom IM, Lin M, Geschwind JF. Improved Visibility of Metastatic Disease in the Liver During Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam Lee H, Lenis D, Stuart EA, Nonyane BA, Pekurovsky F. Irreversible Electroporation in Interventional Oncology: Where We Stand Hansis Chen R, Duran R, Chapiro J, Sheu YR, Kobeiter H, Grass M, Geschwind JF, Lin M. Automatic bone removal for 3D TACE planning with C-arm CBCT: Evaluation of technical feasibility Minimally Invasive Therapy carcinoma before TACE: comparing single-lesion vs. Duran Sohn JH, Sahu S, Hamm B, Gebauer B, Lin M, Geschwind JF, Chapiro J. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers a new class of agents for loco-regional and systemic therapy of liver cancer and beyond?](http://www.ncbi.nlm.nih.gov/pubmed/26989470)Savic LJ, Chapiro J, Duwe G, Geschwind J. Targeting glucose metabolism in cancer: a new class of agents for loco-regional and systemic therapy of liver cancer and V, Duran R, Lin M, Sohn JH, Sharma KV, Wang Z, Chapiro J, Gacchina Johnson C, Bhagat N, Dreher MR, Sch\u00e4fer D, Woods DL, Lewis AL, Tang Y, Grass M, Wood BJ, Geschwind of Local Tumor Therapies-Do We Have to Think Systemically When Treating Cancer Locally?](http://www.ncbi.nlm.nih.gov/pubmed/26203703)Chapiro J, Geschwind JF. Science to Practice: The Changing Face of Local Tumor Therapies-Do We Have to Think Systemically When High-Intensity Focused Ultrasound Treatment of Uterine Fibroids](http://www.ncbi.nlm.nih.gov/pubmed/26160057)Savic LJ, De Lin M, Duran R, Schernthaner RE, Hamm B, Geschwind JF, Hong K, Chapiro J. Three-Dimensional Quantitative Assessment of Lesion Response to MR-guided High-Intensity Focused Ultrasound Treatment I, Marciscano Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.](http://www.ncbi.nlm.nih.gov/pubmed/26131913)Tacher V, Lin M, Duran R, Yarmohammadi H, Lee H, Chapiro J, Chao M, Wang Z, Frangakis C, Sohn JH, Maltenfort MG, Pawlik T, Geschwind JF. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/26001366)Wang Z, Chen R, Duran R, Zhao Y, Yenokyan G, Chapiro J, Schernthaner R, Radaelli A, Lin M, 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma on contrast-enhanced MR imaging: a study of ROI placement](http://www.ncbi.nlm.nih.gov/pubmed/25994198)Chockalingam A, Duran R, Sohn JH, Schernthaner R, Chapiro J, Lee H, Sahu S, Nguyen S, Geschwind JF, Lin M. Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of Improve Liver Periphery Visualization during Chemoembolization.](http://www.ncbi.nlm.nih.gov/pubmed/26000642)Schernthaner RE, Chapiro J, Sahu S, Withagen P, Duran JH, Radaelli A, van der Bom IM, Geschwind JF, Lin M. Feasibility of a Modified Cone-Beam CT Rotation Trajectory to Improve Liver state of the art future directions](http://www.ncbi.nlm.nih.gov/pubmed/25978585)Duran R, Chapiro J, Schernthaner RE, Geschwind catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions British platform reduces radiation exposure for patients with liver cancer treated with transarterial chemoembolization](http://www.ncbi.nlm.nih.gov/pubmed/25956933)Schernthaner RE, Duran R, Chapiro J, Wang Z, Geschwind JF, Lin M. A new angiographic imaging platform reduces radiation exposure for patients with liver cancer treated with transarterial R, Chen R, Geschwind JF, Lin M. Multimodality 3D Tumor Segmentation in HCC 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver](http://www.ncbi.nlm.nih.gov/pubmed/25636420)Chapiro J, Duran R, Lin Lesage D, Wang Z, LJ, Geschwind JF. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer It A Practical Database Management System to Assist Clinical Research Teams with Data Collection, Organization, and Reporting](http://www.ncbi.nlm.nih.gov/pubmed/25641319)Lee H, Chapiro J, Schernthaner R, Duran R, Wang Z, Gorodetski B, Geschwind JF, Lin M. How I Do It A Practical Database Management System to Assist Clinical Research Teams with Data Collection, Organization, and Reporting Academic Uterine Artery Embolization Using Contrast-Enhanced MR Imaging](http://www.ncbi.nlm.nih.gov/pubmed/25638750)Chapiro J, Duran R, Lin LJ, Lessne ML, Hong K. Three-Dimensional Quantitative Assessment of Uterine Fibroid Response after Uterine Artery Embolization Using Contrast-Enhanced MR Imaging Journal Of of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers](http://www.ncbi.nlm.nih.gov/pubmed/25531387)Chapiro J, Duran R, Lin M, Schernthaner RE, Wang Z, Gorodetski B, Geschwind JF. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Semenza GL, Ewald JF. of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer - The use of imaging biomarkers as predictors of patient survival](http://www.ncbi.nlm.nih.gov/pubmed/25542065)Chapiro J, Duran R, Lin M, Mungo B, Schlachter soft-tissue sarcoma metastases to - The use of imaging biomarkers as predictors of patient survival European RE, Geschwind JF. Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI Expert Review Of Imaging in Patients with HCC after TACE: Diagnostic Accuracy of 3D Quantitative Image Analysis](http://www.ncbi.nlm.nih.gov/pubmed/25028783)Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner MR Imaging in Patients with HCC after TACE: Diagnostic Accuracy of 3D Quantitative of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization](http://www.ncbi.nlm.nih.gov/pubmed/24953419)Duran R, Chapiro J, Frangakis C, Lin of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor intra-arterial therapies sorafenib: we finally found the ultimate staging system for HCC? Nature Reviews Chemoembolization A Quantitative Comparison between CBCT and MDCT](http://www.ncbi.nlm.nih.gov/pubmed/24507426)Wang Z, Lin M, Lesage D, Chen R, Chapiro J, Gu T, Tacher V, Duran R, Geschwind Evaluation of Lipiodol in after A Quantitative Comparison Grieb G, Merk M, Garcia AB, McCrann Meinhardt A, Mizue Y, NikolicPaterson D, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R. The role of macrophage migration inhibitory factor therapies for primary liver cancer: state of the art Expert Review Of Ubiquitination Status of Proteins Bound to p97/VCP*](http://www.ncbi.nlm.nih.gov/pubmed/19826004)Cayli S, Klug J, Chapiro J, Fr\u00f6hlich p97/Valosin-containing Protein (VCP) Controls the Ubiquitination Status of Proteins Bound to p97/VCP* Journal Of is an interventional radiologist who specializes in treating patients with liver cancer. As a physician-scientist, his research focuses on developing new imaging biomarkers to diagnose, characterize, and treat liver cancer. Dr. Chapiro's works includes creating advanced molecular imaging methods and incorporating machine-learning approaches. In addition to his clinical work and research, Dr. Chapiro is an associate editor for the Journal of Hepatology and a member of the American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) Steering Committee. He is also the co-initiator of the Rising Star Student Exchange Program in collaboration with the Charit\u00e9 University Hospital in Berlin and co-directs the Yale Interventional Oncology Research Laboratory. Dr. Chapiro is an assistant professor at Yale School of Medicine in Radiology, Digestive Diseases, and Biomedical Engineering. He is the associate director of the Clinical Core of the Yale Liver Center. Titles - Associate Professor of Radiology and Biomedical Imaging - Associate Professor , Digestive Diseases - Associate Professor , Biomedical Engineering - Principal Investigator, Yale Interventional Oncology Laboratory , Radiology & Biomedical Imaging - Director, Center for Minimally Invasive Therapies, Radiology & Biomedical Imaging - Associate Director, Clinical and Translational Core, Liver Center Education & Training - MD/PhDUniversity of Leipzig - Interventional Radiology ResidentYale New Haven Hospital - Diagnostic Radiology ResidentCharit\u00e9 Universit\u00e4tsmedizin Berlin - Research Fellow in Interventional OncologyThe Johns Hopkins Hospital Languages Spoken - English - Fran\u00e7ais (French) - Deutsch (German) - (Russian) Additional Information [Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion](http://www.ncbi.nlm.nih.gov/pubmed/37439935)Taouli B, Ba-Ssalamah A, Chapiro J, Chhatwal Fowler K, Kang T, Knobloch G, Koh D, Kudo M, Lee J, Murakami T, Pinato D, Ringe K, Song B, Tabrizian P, Wang J, Yoon J, Zeng M, Zhou J, Vilgrain V. Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team 10.1007/s00330-023-09919-z](https://doi.org/10.1007/s00330-023-09919-z). [Predicting tumor baseline MR imaging in patients with early-stage hepatocellular carcinoma using deep machine learning](http://www.ncbi.nlm.nih.gov/pubmed/37165035)Kucukkaya A, Zeevi T, Chai N, Raju R, Haider S, Elbanan M, Petukhova-Greenstein A, Lin M, Onofrey J, Nowak M, Cooper K, Thomas E, Santana J, Gebauer B, Mulligan D, Staib L, Batra R, Chapiro J. Predicting tumor recurrence on baseline MR imaging in patients with early-stage hepatocellular carcinoma using deep machine learning V, Madoff D, Zhang X, Chapiro J. Experimental VX2 Rabbit Liver Tumor Model in Carbon Tetrachloride-Induced Cirrhosis of the Liver Journal Score Comparison of Efficacy and Safety](https://doi.org/10.3390/cancers14235847)Savic L, Chen E, Nezami N, Murali N, Hamm C, Wang C, Lin M, Schlachter T, Hong K, Georgiades C, Chapiro Hepatocellular Carcinoma\u2014A Propensity Score Comparison of Efficacy and Safety](http://www.ncbi.nlm.nih.gov/pubmed/36497329)Savic L, Chen E, Nezami N, Murali N, Hamm C, Wang C, Lin M, Schlachter T, Hong K, Georgiades C, Chapiro J, Unresectable Hepatocellular Carcinoma\u2014A Propensity after Radiofrequency Ablation of the Liver](http://www.ncbi.nlm.nih.gov/pubmed/36423815)Santana J, Petukhova-Greenstein A, Gross M, Hyder F, Pekurovsky V, Gottwald L, Boustani A, Walsh J, Kucukkaya A, Malpani R, Madoff D, Goldberg S, Ahmed M, Joshi N, Coman D, Chapiro J. MR Imaging-Based In Vivo Macrophage Imaging to Monitor Immune Response after Radiofrequency Ablation of the Liver Journal radiation therapy of hepatocellular carcinoma: an international expert study](http://www.ncbi.nlm.nih.gov/pubmed/36282299)Gregory J, Tselikas L, Allimant C, de Baere T, Bargellini I, Bell J, Bilbao JI, Bouvier A, Chapiro J, Chiesa C, Decaens J, Helmberger T, Irani F, Lam M, Lewandowski R, Liu D, Loffroy R, Madoff DC, Mastier C, Salem R, Sangro B, Sze D, Vilgrain V, Vouche M, Guiu B, Ronot M. Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study European Journal Of Nuclear Medicine And Molecular Imaging 2022, 50: 921-928. [PMID: Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical Study.](http://www.ncbi.nlm.nih.gov/pubmed/35975886)Iseke S, Zeevi Kucukkaya Haider SP, Petukhova-Greenstein A, Kuhn TN, Lin M, Nowak M, Cooper K, Thomas E, Weber MA, Madoff DC, Staib L, Batra R, Chapiro J. Machine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective van Breugel JMM, S, Rexha I, Tegel LJ, Hong K, Georgiades C, Nezami N. Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A of Interventional Radiology Foundation Research Consensus Panel on Artificial Intelligence in Interventional Radiology: From Code to Bedside](http://www.ncbi.nlm.nih.gov/pubmed/35871021)Chapiro J, Allen B, Abajian A, Wood B, Kothary N, Daye D, Bai H, Sedrakyan A, Diamond M, Simonyan V, McLennan G, Abi-Jaoudeh N, Pua B. Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel on Artificial Intelligence in Interventional Radiology: From Code to Bedside Journal Of P, Camacho JC, Nezami N. Intraarterial Therapies Chapiro Georgiades C, Hong KK, Nezami N. Response assessment methods for patients with hepatic metastasis from rare tumor primaries after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features](http://www.ncbi.nlm.nih.gov/pubmed/35460887)Petukhova-Greenstein A, Zeevi T, Yang J, Chai N, DiDomenico P, Deng Y, Ciarleglio M, Haider SP, Onyiuke I, Malpani R, Lin G, Taddei T, Chapiro J. MR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features Journal Of for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at T, Nezami N, Strazzabosco Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden towards AI-driven predictive biomarkers for immunotherapy of hepatocellular carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/35417743)Chapiro J. Translating artificial intelligence from code to bedside: The road towards AI-driven predictive biomarkers for on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model](http://www.ncbi.nlm.nih.gov/pubmed/35346859)Berz JG, Iseke M, Zhang X, Schlachter T, Madoff DC, Chapiro J. Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor intelligence liver improving Imaging Acquired during Transarterial Chemoembolization for Liver Tumors: A Deep Learning Approach](http://www.ncbi.nlm.nih.gov/pubmed/34923098)Malpani R, Petty CW, Yang J, Bhatt N, Zeevi T, Chockalingam V, Raju JG, Schlachter TR, Madoff DC, Chapiro J, Duncan J, Lin M. Quantitative Automated Segmentation of Lipiodol Deposits on Cone-Beam CT Imaging Acquired during Transarterial Chemoembolization for Liver Tumors: A Deep Learning Approach Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative.](http://www.ncbi.nlm.nih.gov/pubmed/34581627)Puijk RS, Ahmed M, Adam A, Arai Y, Arellano R, de Ba\u00e8re T, Bale R, Bellera Binkert Brace DJ, E, Gangi A, Gervais DA, Gillams AR, Greene T, Guiu B, Helmberger T, Iezzi R, Kang TW, Kelekis A, Kim HS, Kr\u00f6ncke T, Kwan S, Lee MW, Lee FT, Lee EW, Liang P, Lissenberg-Witte BI, Lu DS, Madoff DC, Mauri G, Meloni MF, Morgan R, Nadolski G, Narayanan G, Newton I, Nikolic B, Orsi F, Pereira PL, Pua U, Rhim H, W, TJ, Wang DS, Wood BJ, Goldberg SN, Meijerink MR. Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging](http://www.ncbi.nlm.nih.gov/pubmed/34852007)Gross M, Spektor M, Jaffe A, Kucukkaya AS, Iseke S, Haider SP, Strazzabosco M, Chapiro J, Onofrey JA. Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure](http://www.ncbi.nlm.nih.gov/pubmed/34804911)Frangakis C, Sohn JH, Bas A, Chapiro J, Schernthaner RE, Lin M, Hamilton JP, Pawlik TM, Hong K, Duran R. Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Recurrent Hepatocellular Carcinoma: Worth the Risk?](http://www.ncbi.nlm.nih.gov/pubmed/34717834)Nam D, Chapiro J. Machine Learning-Based Surveillance Strategy after Complete Ablation of Initially Recurrent Hepatocellular Carcinoma: Worth the chemoembolic in CA, Gebauer B, Walsh JJ, Rexha I, Hyder F, Lin M, Madoff DC, Schlachter T, Chapiro J, Coman D. Comparison of responses to transarterial chemoembolization with different chemoembolic regimens in M, Hong K, Georgiades C. Lipiodol Deposition and Washout in Primary and Interventional Radiology: Current State and Future Directions](http://www.ncbi.nlm.nih.gov/pubmed/35005333)Malpani R, Petty C, Bhatt N, Staib L, Chapiro J. Use of Artificial Intelligence in Nononcologic Interventional Radiology: Current State and Future in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy](http://www.ncbi.nlm.nih.gov/pubmed/34061209)Ghani MA, Fereydooni A, Chen E, Letzen B, Laage-Gaupp F, Nezami N, Deng Y, Gan G, Thakur V, Lin M, Papademetris X, Schernthaner RE, Huber S, Chapiro J, Hong K, Georgiades C. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial](http://www.ncbi.nlm.nih.gov/pubmed/34022765)Letzen BS, R, Miszczuk M, de Ruiter QMB, Petty Rexha Nezami Laage-Gaupp F, M, Schlachter TR, Chapiro J. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma](http://www.ncbi.nlm.nih.gov/pubmed/33927226)Rexha I, Laage-Gaupp F, Konstantinidis Duran R, Gebauer B, Georgiades C, Hong K, Nezami N. Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of SPION-Enhanced J, Savic Hepatic Radiofrequency Ablation: Monitoring the DC, Robinson SP, Karst U, Buchholz R, Keller S, Hamm B, Goldberg SN, MR. Elastin-specific MRI of extracellular matrix-remodelling following hepatic truth: Application to intraprocedural CBCT/MR liver segmentation and registration](http://www.ncbi.nlm.nih.gov/pubmed/33823397)Zhou B, Augenfeld Z, Chapiro J, Zhou SK, Liu C, Duncan JS. Anatomy-guided multimodal registration by learning segmentation without ground truth: Application to intraprocedural CBCT/MR liver segmentation and patients with small (<3 cm) hepatocellular carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/33592550)Chai Chapiro J, Petukhova Zeevi T, Elbanan M, M, JS, Madoff vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 After Transarterial Chemoembolization](http://www.ncbi.nlm.nih.gov/pubmed/33484726)Wu X, Chapiro J, Malhotra A. Cost-Effectiveness of Imaging Tumor Response Criteria in Hepatocellular Cancer After Transarterial Chemoembolization Journal Of hepatocellular carcinoma (HCC) versus non-HCC on of the liver](http://www.ncbi.nlm.nih.gov/pubmed/33409782)Oestmann PM, Wang CJ, Savic LJ, Hamm CA, Stark S, Schobert I, Gebauer Schlachter T, Lin M, Weinreb JC, Batra R, Mulligan D, Zhang X, Duncan JS, Chapiro J. Deep learning-assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on Trilla A, M\u00e4hringer-Kunz A, Hahn F, D\u00fcber C, Becker B, Dos Santos DP, Kloeckner R. How COVID-19 kick-started online learning of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice Cost-Effectiveness Analysis](http://www.ncbi.nlm.nih.gov/pubmed/33160827)Wu Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on LA, J, T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on Improved Probability Calibration and Classification](http://www.ncbi.nlm.nih.gov/pubmed/32356739)Zhang F, Dvornek N, Yang J, Chapiro J, Duncan J. Layer Embedding Analysis in Convolutional Neural Networks for Improved Probability Calibration and Classification IEEE biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer](http://www.ncbi.nlm.nih.gov/pubmed/33093524)Stark S, Wang M, Murali Gebauer B, Lin M, Duncan J, Schlachter T, Chapiro J. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer marker for doxorubicin pharmacokinetics during transarterial JH, S, P, MA, Perez Lozada JC, Ayyagari R, Pollak J, Schlachter T. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma](http://www.ncbi.nlm.nih.gov/pubmed/32938221)Auer TA, Della Seta M, Collettini F, Chapiro J, Zschaeck Ghadjar P, Badakhshi H, Florange J, Hamm B, Budach V, Kaul D. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients Field Correction Effect on 3D-quantitative Image Analysis](http://www.ncbi.nlm.nih.gov/pubmed/33083252)Liu C, Smolka S, Papademetris X, Do Minh D, Gan G, Deng Y, Lin M, Chapiro J, Wang X, Georgiades C, Hong K. Predicting Infiltrative Hepatocellular Carcinoma Patient Outcome Post-TACE: MR Bias Field Correction Effect on 3D-quantitative Image Analysis Journal Of Clinical Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment](http://www.ncbi.nlm.nih.gov/pubmed/32684417)Borde Gaupp F, Geschwind JF, Savic LJ, Miszczuk M, I, Adam L, Walsh JJ, Huber S, Duncan JS, Peters DC, Sinusas A, Schlachter T, Chemoembolization in a Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment Journal Of Vascular a Rabbit Liver Tumor Model: A Biomarker Resistance Mechanisms in Tumor-targeted Therapy?](http://www.ncbi.nlm.nih.gov/pubmed/32633675)Savic LJ, Doemel LA, Schobert IT, Montgomery RR, Joshi N, Walsh JJ, Santana J, Pekurovsky V, Zhang X, Lin M, Adam L, Boustani A, Duncan J, Leng L, Bucala RJ, Goldberg SN, Hyder F, Coman D, Chapiro J. Molecular MRI of the Immuno-Metabolic Interplay in a Rabbit Liver Tumor Model: A Biomarker using LH, M, J, Lin M. detection and delineation of hepatocellular carcinoma on multiphasic contrast-enhanced MRI correlation](http://www.ncbi.nlm.nih.gov/pubmed/32430483)Tefera J, Revzin Mulligan D, X. hepatocellular carcinoma\u2014a new variant of liver cancer: clinical, pathological and radiological correlation Journal Of carcinoma after DEB-TACE](http://www.ncbi.nlm.nih.gov/pubmed/32424595)Schobert IT, Savic LJ, Chapiro Chen Nezami N, Lin M, Pollak J, Schlachter T. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in biomarker for disease progression of renal cell carcinoma after tumor ablation](http://www.ncbi.nlm.nih.gov/pubmed/32216452)Tegel BR, Huber S, Savic LJ, Lin M, Gebauer B, Pollak J, Chapiro J. Quantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after Chapiro J. Supervised Machine Learning in Oncology: A Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32092672)Miszczuk MA, Chapiro J, Geschwind JH, E, Schlachter T. Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment](http://www.ncbi.nlm.nih.gov/pubmed/31582517)Savic LJ, Schobert I, Peters D, Walsh JJ, Laage-Gaupp F, Hamm CA, Tritz N, Doemel LA, Lin M, Sinusas A, Schlachter T, Duncan JS, Hyder F, Coman D, Chapiro J. Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment Clinical cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT?](http://www.ncbi.nlm.nih.gov/pubmed/31811428)Luedemann WM, Geisel Gebauer B, Schnapauff D, Chapiro J. Comparing HCC tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ Pua U. Interventional oncology: aiming globally to be the 4 th pillar of cancer care Chinese Clinical Oncology 2019, 8: Lower Urinary Tract Symptoms Attributable to Benign Prostatic Hyperplasia: A Single-Center Outcomes Analysis with Medium-Term Follow-up](http://www.ncbi.nlm.nih.gov/pubmed/31771896)Ayyagari R, Powell T, Staib L, Chapiro J, Raja A, Bhatia S, Chai T, S, R. Prostatic Artery Embolization Using 100-300-m Trisacryl Gelatin Microspheres to Treat Lower Urinary Tract Symptoms Attributable to Benign Prostatic Hyperplasia: A Single-Center Outcomes Analysis with Medium-Term R, Powell T, Staib L, Chapiro J, Perez-Lozada JC, Bhatia S, Chai T, Schoenberger S, C, Collettini F, Sack I, Savic LJ, Hamm B, Goldberg SN, Makowski M. Quantitative MRI for Assessment of Treatment Outcomes in a Rabbit VX2 Hepatic Tumor Model Journal Of Magnetic Resonance 668-685. [PMID: 31713973](https://pubmed.ncbi.nlm.nih.gov/31713973), [DOI: Savic LJ, Huber S, Sinusas AJ, Lin M, Chapiro J, Constable RT, Rothman DL, Duncan JS, Hyder F. Extracellular pH mapping of liver cancer on a clinical 3T MRI scanner Magnetic Resonance In Liver Segmentation](http://www.ncbi.nlm.nih.gov/pubmed/32377643)Yang J, Dvornek NC, Zhang F, Chapiro J, Lin M, Duncan JS. Unsupervised Domain Adaptation via Disentangled Representations: NC, Zhang F, Zhuang J, Chapiro J, Lin M, Duncan JS. Domain-Agnostic Learning with Anatomy-Consistent Embedding for to Bedside: Introducing Predictive Intelligence to Interventional Oncology Radiology Primary and Metastatic D, Saperstein to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Embolization for Treatment of Benign Hyperplasia](http://www.ncbi.nlm.nih.gov/pubmed/31375451)Ayyagari R, Powell T, Staib L, Chapiro J, Schoenberger Devito R, versus Balloon-Occlusion Microcatheter Artery Embolization for Treatment of Benign M, Chapiro J. application of lipiodol for transarterial chemoembolization in neural network interpretation JC, Duncan JS, Chapiro J, Letzen B. Deep learning for liver tumor diagnosis part II: convolutional neural network interpretation using of a convolutional neural JS, Weinreb JC, Chapiro J, Letzen B. Deep learning for liver tumor diagnosis part I: development of a convolutional neural network Interventional Oncology White Paper](http://www.ncbi.nlm.nih.gov/pubmed/31012818)Erinjeri JP, Fine GC, GJ, Ahmed J, Brok M, Duran R, Hunt SJ, Johnson DT, Ricke J, Sze DY, Toskich BB, Wood BJ, Woodrum D, Goldberg SN. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities\u2014A Society pre-treatment MRI predicts overall survival after stereotactic radiation therapy of patients with a singular brain metastasis](http://www.ncbi.nlm.nih.gov/pubmed/30841703)Della Seta M, Collettini F, Chapiro J, Angelidis A, Engeling F, Hamm B, Kaul D. A 3D quantitative imaging biomarker in pre-treatment MRI predicts overall survival after stereotactic radiation therapy of patients with a singular Chapiro Nezami Gebauer M, Pollak J, Saperstein L, Schlachter T, Bremsstrahlung J. The Role of Artificial Intelligence in Interventional Oncology: A Primer Journal Of Vascular Prospective Single-Center Phase I Study](http://www.ncbi.nlm.nih.gov/pubmed/30337148)Fereydooni A, Letzen B, Ghani MA, Cancer Liver Metastases: A Prospective Single-Center Phase I Study Journal Of Learning: An Example for Trans-Arterial Geschwind JF, Chapiro J. Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma. Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma](https://doi.org/10.3791/58382-v)Abajian A, Murali N, Savic L, Laage-Gaupp F, Nezami Duncan J, Schlachter T, Lin M, Geschwind J, Chapiro J. Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma Journal Of Visualized Experiments 2018 [DOI: 10.3791/58382-v](https://doi.org/10.3791/58382-v). [Liver Tissue Classification Using an Auto-context-based Deep Neural Network with a Multi-phase Training Framework](http://www.ncbi.nlm.nih.gov/pubmed/32432233)Zhang F, Yang J, Nezami N, Laage-gaupp F, Chapiro J, De Lin M, Duncan J. Liver Tissue Classification Using an Auto-context-based Deep Neural Network with a Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning\u2014An Artificial Intelligence Concept](http://www.ncbi.nlm.nih.gov/pubmed/29548875)Abajian A, Murali Geschwind JF, Chapiro J. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning\u2014An Artificial Intelligence Concept Journal Of Vascular Streitparth F. Off-Target Effects-Is Network Pathway Analysis the Final Piece of the Puzzle?](http://www.ncbi.nlm.nih.gov/pubmed/29356646)Murali N, Laage-Gaupp FM, Chapiro J, Geschwind Enigma of Ablation-induced Off-Target Effects-Is Network Pathway Analysis the Final Delivery in Combination X-Ray Imaging System for Interventional Procedures: Improved Image Quality and Reduced Radiation Dose](http://www.ncbi.nlm.nih.gov/pubmed/29090348)Schernthaner RE, Haroun RR, Nguyen S, Duran R, Sohn JH, Sahu S, Chapiro J, Zhao Y, Radaelli A, van der Bom IM, Mauti M, Hong K, Geschwind JH, Lin M. Characteristics of a New X-Ray Imaging System for Interventional Procedures: Improved Image Quality and Reduced Radiation Dose CardioVascular 3D Guidance in Portal Vein Embolization (PVE)](http://www.ncbi.nlm.nih.gov/pubmed/28875339)L\u00fcdemann WM, B\u00f6ning G, Chapiro Cone Beam CT for Intraprocedural Image Fusion and 3D Guidance in Portal Vein Embolization Carcinoma by Fusing Structured and Rotationally Invariant Context Representation](http://www.ncbi.nlm.nih.gov/pubmed/29900427)Treilhard J, Smolka S, Staib L, Chapiro J, Lin M, Shakirin G, Duncan J. Liver Tissue Classification in Patients with Hepatocellular Carcinoma by Fusing Structured and before Transarterial Chemoembolization](http://www.ncbi.nlm.nih.gov/pubmed/28747271)Jonczyk M, Chapiro J, Collettini F, Geisel D, Schnapauff D, Streitparth F, Schmidt T, Hamm B, Gebauer B, G. Diagnostic Accuracy of Split-Bolus Single-Phase Contrast-Enhanced Cone-Beam CT for the Detection of Liver yttrium-90 radioembolisation as treatment options using a propensity score analysis model](http://www.ncbi.nlm.nih.gov/pubmed/28677067)Do Minh D, Chapiro J, Gorodetski B, Huang Q, Liu C, Smolka S, Savic LJ, yttrium-90 radioembolisation as treatment options with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/28668723)Smolka S, Chapiro J, Manzano W, Treilhard J, Reiner E, Deng Y, Zhao Y, Hamm B, Duncan JS, Gebauer B, Lin M, Geschwind JF. The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma to Complete Response in Chemoembolization?](http://www.ncbi.nlm.nih.gov/pubmed/28514219)Savic LJ, Chapiro J, Dormant Cells\u2014Is Targeting Autophagy the Key to J, J, M, CP, JF. Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with therapies for liver cancer: assessing tumor response Expert Review 119-127. [PMID: 27983883](https://pubmed.ncbi.nlm.nih.gov/27983883), [DOI: 10.1080/14737140.2017.1273775](https://doi.org/10.1080/14737140.2017.1273775). [Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy](http://www.ncbi.nlm.nih.gov/pubmed/27847278)Sohn JH, Duran R, Zhao Y, Fleckenstein F, Chapiro J, Sahu S, Schernthaner RE, Qian T, Lee H, Zhao L, Hamilton J, Frangakis C, Lin M, Salem R, Geschwind JF. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy Clinical Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?](http://www.ncbi.nlm.nih.gov/pubmed/27831830)Sahu S, Schernthaner R, Ardon R, Chapiro J, Zhao JH, F, Lin M, Geschwind JF, Duran R. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Geschwind JH. From the Guest Editor JF. Interventional Oncology S, Fleckenstein F, Smolka S, Pawlik TM, Schernthaner R, Zhao L, Lee H, He S, Lin M, Geschwind JF. Transarterial Chemoembolization for the Treatment of Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis](http://www.ncbi.nlm.nih.gov/pubmed/27641641)Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Marshall K, Lin M, Gebauer B, Chapiro J, Salem R, Geschwind JF. Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement and Myths Exposed?](http://www.ncbi.nlm.nih.gov/pubmed/27429140)Chapiro J, Geschwind JF. Science to Practice: Systemic Implications of Sorafenib in Combination Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma. Clinical And [PMID: 27487101](https://pubmed.ncbi.nlm.nih.gov/27487101). Metastatic in During Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam CT](http://www.ncbi.nlm.nih.gov/pubmed/27380872)Schernthaner RE, Haroun Duran R, Lee Sahu Sohn JH, Chapiro J, Zhao Y, Gorodetski B, Fleckenstein F, Smolka S, Radaelli A, van der Bom IM, Lin M, Geschwind JF. Improved Visibility of Metastatic Disease in the Liver During Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam Lee H, Lenis D, Stuart EA, Nonyane BA, Pekurovsky F. Irreversible Electroporation in Interventional Oncology: Where We Stand Hansis Chen R, Duran R, Chapiro J, Sheu YR, Kobeiter H, Grass M, Geschwind JF, Lin M. Automatic bone removal for 3D TACE planning with C-arm CBCT: Evaluation of technical feasibility Minimally Invasive Therapy carcinoma before TACE: comparing single-lesion vs. Duran Sohn JH, Sahu S, Hamm B, Gebauer B, Lin M, Geschwind JF, Chapiro J. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers a new class of agents for loco-regional and systemic therapy of liver cancer and beyond?](http://www.ncbi.nlm.nih.gov/pubmed/26989470)Savic LJ, Chapiro J, Duwe G, Geschwind J. Targeting glucose metabolism in cancer: a new class of agents for loco-regional and systemic therapy of liver cancer and V, Duran R, Lin M, Sohn JH, Sharma KV, Wang Z, Chapiro J, Gacchina Johnson C, Bhagat N, Dreher MR, Sch\u00e4fer D, Woods DL, Lewis AL, Tang Y, Grass M, Wood BJ, Geschwind of Local Tumor Therapies-Do We Have to Think Systemically When Treating Cancer Locally?](http://www.ncbi.nlm.nih.gov/pubmed/26203703)Chapiro J, Geschwind JF. Science to Practice: The Changing Face of Local Tumor Therapies-Do We Have to Think Systemically When High-Intensity Focused Ultrasound Treatment of Uterine Fibroids](http://www.ncbi.nlm.nih.gov/pubmed/26160057)Savic LJ, De Lin M, Duran R, Schernthaner RE, Hamm B, Geschwind JF, Hong K, Chapiro J. Three-Dimensional Quantitative Assessment of Lesion Response to MR-guided High-Intensity Focused Ultrasound Treatment I, Marciscano Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.](http://www.ncbi.nlm.nih.gov/pubmed/26131913)Tacher V, Lin M, Duran R, Yarmohammadi H, Lee H, Chapiro J, Chao M, Wang Z, Frangakis C, Sohn JH, Maltenfort MG, Pawlik T, Geschwind JF. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/26001366)Wang Z, Chen R, Duran R, Zhao Y, Yenokyan G, Chapiro J, Schernthaner R, Radaelli A, Lin M, 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma on contrast-enhanced MR imaging: a study of ROI placement](http://www.ncbi.nlm.nih.gov/pubmed/25994198)Chockalingam A, Duran R, Sohn JH, Schernthaner R, Chapiro J, Lee H, Sahu S, Nguyen S, Geschwind JF, Lin M. Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of Improve Liver Periphery Visualization during Chemoembolization.](http://www.ncbi.nlm.nih.gov/pubmed/26000642)Schernthaner RE, Chapiro J, Sahu S, Withagen P, Duran JH, Radaelli A, van der Bom IM, Geschwind JF, Lin M. Feasibility of a Modified Cone-Beam CT Rotation Trajectory to Improve Liver state of the art future directions](http://www.ncbi.nlm.nih.gov/pubmed/25978585)Duran R, Chapiro J, Schernthaner RE, Geschwind catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions British platform reduces radiation exposure for patients with liver cancer treated with transarterial chemoembolization](http://www.ncbi.nlm.nih.gov/pubmed/25956933)Schernthaner RE, Duran R, Chapiro J, Wang Z, Geschwind JF, Lin M. A new angiographic imaging platform reduces radiation exposure for patients with liver cancer treated with transarterial R, Chen R, Geschwind JF, Lin M. Multimodality 3D Tumor Segmentation in HCC 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver](http://www.ncbi.nlm.nih.gov/pubmed/25636420)Chapiro J, Duran R, Lin Lesage D, Wang Z, LJ, Geschwind JF. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer It A Practical Database Management System to Assist Clinical Research Teams with Data Collection, Organization, and Reporting](http://www.ncbi.nlm.nih.gov/pubmed/25641319)Lee H, Chapiro J, Schernthaner R, Duran R, Wang Z, Gorodetski B, Geschwind JF, Lin M. How I Do It A Practical Database Management System to Assist Clinical Research Teams with Data Collection, Organization, and Reporting Academic Uterine Artery Embolization Using Contrast-Enhanced MR Imaging](http://www.ncbi.nlm.nih.gov/pubmed/25638750)Chapiro J, Duran R, Lin LJ, Lessne ML, Hong K. Three-Dimensional Quantitative Assessment of Uterine Fibroid Response after Uterine Artery Embolization Using Contrast-Enhanced MR Imaging Journal Of of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers](http://www.ncbi.nlm.nih.gov/pubmed/25531387)Chapiro J, Duran R, Lin M, Schernthaner RE, Wang Z, Gorodetski B, Geschwind JF. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Semenza GL, Ewald JF. of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer - The use of imaging biomarkers as predictors of patient survival](http://www.ncbi.nlm.nih.gov/pubmed/25542065)Chapiro J, Duran R, Lin M, Mungo B, Schlachter soft-tissue sarcoma metastases to - The use of imaging biomarkers as predictors of patient survival European RE, Geschwind JF. Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI Expert Review Of Imaging in Patients with HCC after TACE: Diagnostic Accuracy of 3D Quantitative Image Analysis](http://www.ncbi.nlm.nih.gov/pubmed/25028783)Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner MR Imaging in Patients with HCC after TACE: Diagnostic Accuracy of 3D Quantitative of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization](http://www.ncbi.nlm.nih.gov/pubmed/24953419)Duran R, Chapiro J, Frangakis C, Lin of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor intra-arterial therapies sorafenib: we finally found the ultimate staging system for HCC? Nature Reviews Chemoembolization A Quantitative Comparison between CBCT and MDCT](http://www.ncbi.nlm.nih.gov/pubmed/24507426)Wang Z, Lin M, Lesage D, Chen R, Chapiro J, Gu T, Tacher V, Duran R, Geschwind Evaluation of Lipiodol in after A Quantitative Comparison Grieb G, Merk M, Garcia AB, McCrann Meinhardt A, Mizue Y, NikolicPaterson D, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R. The role of macrophage migration inhibitory factor therapies for primary liver cancer: state of the art Expert Review Of Ubiquitination Status of Proteins Bound to p97/VCP*](http://www.ncbi.nlm.nih.gov/pubmed/19826004)Cayli S, Klug J, Chapiro J, Fr\u00f6hlich p97/Valosin-containing Protein (VCP) Controls the Ubiquitination Status of Proteins Bound to p97/VCP* Journal Of "}